TABLE 1.
Patient baseline characteristics
| Cohort A1: cHL (anti‐PD‐1/PD‐L1 naïve) (n = 18) | Cohort A2: cHL (anti‐PD‐1/PD‐L1 progressors) (n = 12) | Cohort B: DLBCL (n = 17) | Cohort C: PTCL (n = 11) | |
|---|---|---|---|---|
| Age, years, median (range) | 36.0 (21–87) | 33.0 (19–68) | 64.0 (23–75) | 69.0 (50–77) |
| Male | 10 (55.6) | 7 (58.3) | 12 (70.6) | 7 (63.6) |
| ECOG performance status | ||||
| 0 | 14 (77.8) | 9 (75.0) | 5 (29.4) | 3 (27.3) |
| 1 | 4 (22.2) | 3 (25.0) | 11 (64.7) | 8 (72.7) |
| 2 | 0 | 0 | 1 (5.9) | 0 |
| Staging | ||||
| Stage I | 0 | 0 | 0 | 0 |
| Stage II | 1 (5.6) | 4 (33.3) | 1 (5.9) | 1 (9.1) |
| Stage II bulky | 1 (5.6) | 0 | 1 (5.9) | 0 |
| Stage III | 4 (22.2) | 4 (33.3) | 3 (17.6) | 1 (9.1) |
| Stage IV | 12 (66.7) | 4 (33.3) | 12 (70.6) | 9 (81.8) |
| Number of prior regimens | ||||
| 1 | 0 | 0 | 0 | 10 (90.9) |
| 2 | 0 | 0 | 14 (82.4) | 0 |
| >2 | 18 (100) | 12 (100) | 3 (17.6) | 1 (9.1) |
| Subtype | ||||
| Lymphocyte‐rich cHL | 1 (5.6) | 1 (9.1) | NA | NA |
| Mixed‐cellularity cHL | 3 (16.7) | 2 (18.2) | NA | NA |
| Nodular‐sclerosis cHL | 14 (77.8) | 8 (72.7) | NA | NA |
| DLBCL, NOS | NA | NA | 12 (70.6) | NA |
| High‐grade lymphomas with translocations of MYC and BCL2 and/or BCL6 (double/triple‐hit lymphoma) | NA | NA | 1 (5.9) | NA |
| Other | NA | NA | 3 (17.6) | NA |
| T‐cell/histiocyte‐rich large B‐cell lymphoma | NA | NA | 1 (5.9) | NA |
| Angioimmunoblastic T‐cell lymphoma | NA | NA | NA | 5 (45.5) |
| PTCL, NOS | NA | NA | NA | 6 (54.5) |
| Time from initial diagnosis to first dose in years, median (range) | 2.56 (0.8–8.3) | 3.38 (1.3–20.9) | 1.19 (0.3–7.7) | 1.26 (0.3–6.5) |
| International Prognostic Score at study entry a | ||||
| 0 | 0 | 2 (16.7) | 0 | 0 |
| 1 | 4 (22.2) | 4 (33.3) | 1 (5.9) | 1 (9.1) |
| 2 | 6 (33.3) | 3 (25.0) | 1 (5.9) | 2 (18.2) |
| 3 | 4 (22.2) | 3 (25.0) | 10 (58.8) | 5 (45.5) |
| 4 | 1 (5.6) | 0 | 4 (23.5) | 3 (27.3) |
| 5 | 2 (11.1) | 0 | 1 (5.9) | 0 |
| 6 | 1 (5.6) | 0 | 0 | 0 |
Note: All data are shown as n (%), except where otherwise indicated.
Abbreviations: BCL, B‐cell lymphoma; cHL, classic Hodgkin's lymphoma; DLBCL, diffuse large B‐cell lymphoma; ECOG, Eastern Cooperative Oncology Group; MYC, myelocytomatosis; NA, not applicable; NOS, not otherwise specified; PD‐1, programmed death‐1; PD‐L1, programmed death ligand‐1; PTCL, peripheral T‐cell lymphoma.
Different risk factors are used to calculate the International Prognostic Score for cHL, DLBCL, and PTCL. For cHL cohorts, 1 point is added with the presence of each of the following criteria: age ≥45 years; albumin <4 g/dl; hemoglobin <10.5 g/dl; leukocytosis (white blood cell count ≥15,000/mm3); lymphocytopenia (lymphocyte count <8% of white blood cell count, and/or lymphocyte count <600/mm3); male; stage IV disease. For DLBCL and PTCL cohorts, 1 point is added with the presence of each of the following criteria: age >60; Ann Arbor stage III or IV; ECOG performance status ≥2; serum lactate dehydrogenase level >1 × normal; >1 extranodal site.